Dalcetrapib(JTT-705;RO4607381)/ supplier with competitive price in stock-Rechems CAS NO.211513-37-0

1.Custom synthetic service could be provided and COA/HPLC/HNMR is available.
2.Professional synthesis laboratory and production base.
3.Strong synthesis team and service team.
4.Professional data management system.
5.We provide the professional test date and product information.
6.Rich shipping methods,ex. Fedex,DHL,TNT,BY SEA and BY AIR.
7. We can accept various payment methods,Paypal,T/T, etc.
8.Professional packaging can be according the customers’requirment.

Dalcetrapib (JTT-705; RO-4607381) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol.IC50 value: 0.2 uM Target: CETP in vitro: Dalcetrapib modulates CETP activity.Dalcetrapib induces a conformational change in CETP, when added to human plasma.CETP-induced pre-β-HDL formation in human plasma is unchanged by Dalcetrapib ≤3 μM and increased at 10 μM.Dalcetrapib statistically and significantly increases pre-β-HDL formation .Dalcetrapib achieves 50% inhibition of CETP activity in human plasma at a concentration of 9 μM .Dalcetrapib inhibits the CETP activity of media in HepG2 in a dose-dependent manner .in vivo: Treatment with Dalcetrapib leads to significant increases in HDL-C levels.In hamsters injected with [3H]cholesterol-labeled autologous macrophages Dalcetrapib significantly increases fecal elimination of both [3H]neutral sterols and [3H]bile acids.Dalcetrapib increases plasma HDL-[3H]cholesterol .Dalcetrapib has 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg.Dalcetrapib increases the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 mg/kg or 100 mg/kg once a day for 3 days to male Japanese white rabbits .
Shanghai Rechem science Co., Ltd.
Rechemsis focus on R&D of new APIS, signal transduction inhibitors and pharmaceutical intermediates. We follow closely the industry trend, and the latest research achievements in life science area.
Rechems is located in the largest biomedical base in China--Shanghai and cooperatively established modern production base and laboratory in surrounding areas. We have built up a good relationship with many US / European / Japanese pharmaceutical companies to conduct chemical research and inventory trading in medicinal chemistry.
Rechems's mission is to serve pharmaceutical community by providing excellent services and high-quality products in a timely manner.
Rechems's vision is to be recognized by our clients as one of the best suppliers of chemical products for our superior quality, efficient and cost-effective services.
We insist the principle of "Quality first, customer foremost, best credit, be pioneering and creative", looking forward to establishing good business relationships with customers all over the world. Let's work together for bright future!